| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and
Unité d’Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France
HIV epitopes may have developed to be poor immunogens. As a counterapproach HIV vaccine strategy, we used epitope enhancement of a conserved HIV reverse transcriptase (RT) epitope for induction of antiviral protection in HLA-A2-transgenic mice mediated by human HLA-A2-restricted CTLs. We designed two epitope-enhanced peptides based on affinity for HLA-A2, one substituted in anchor residues (RT-2L9V) and the other also with tyrosine at position 1 (RT-1Y2L9V), and examined the balance between HLA binding and T cell recognition. CTL lines and bulk cultures in two HLA-A2-transgenic mouse strains showed that RT-2L9V was more effective in inducing CTL reactive with wild-type Ag than RT-1Y2L9V, despite the higher affinity of the latter, because the 1Y substitution unexpectedly altered T cell recognition. Accordingly, RT-2L9V afforded the greatest protection in vivo against a surrogate virus expressing HIV-1 RT mediated by HLA-A2-restricted CTL in a mouse in which all CTL are restricted to only the human HLA molecule. Such antiviral protection has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor cross-reactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.
This article has been cited by other articles:
|
|
 |
|
  T. Okazaki, M. Terabe, A. T. Catanzaro, C. D. Pendleton, R. Yarchoan, and J. A. Berzofsky Possible Therapeutic Vaccine Strategy against Human Immunodeficiency Virus Escape from Reverse Transcriptase Inhibitors Studied in HLA-A2 Transgenic Mice J. Virol., November 1, 2006; 80(21): 10645 - 10651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okazaki, C. D. Pendleton, P. Sarobe, E. K. Thomas, S. Iyengar, C. Harro, D. Schwartz, and J. A. Berzofsky Epitope Enhancement of a CD4 HIV Epitope toward the Development of the Next Generation HIV Vaccine J. Immunol., March 15, 2006; 176(6): 3753 - 3759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. van den Broeke, C. D. Pendleton, C. Mackall, L. J. Helman, and J. A. Berzofsky Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors Cancer Res., February 1, 2006; 66(3): 1818 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. McKinney, R. Skvoretz, B. D. Livingston, C. C. Wilson, M. Anders, R. W. Chesnut, A. Sette, M. Essex, V. Novitsky, and M. J. Newman Recognition of Variant HIV-1 Epitopes from Diverse Viral Subtypes by Vaccine-Induced CTL J. Immunol., August 1, 2004; 173(3): 1941 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Snyder, I. M. Belyakov, A. Dzutsev, F. Lemonnier, and J. A. Berzofsky Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses J. Virol., July 1, 2004; 78(13): 7052 - 7060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oh, M. Terabe, C. D. Pendleton, A. Bhattacharyya, T. K. Bera, M. Epel, Y. Reiter, J. Phillips, W. M. Linehan, C. Kasten-Sportes, et al. Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells Cancer Res., April 1, 2004; 64(7): 2610 - 2618. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
